ASX:BNO Bionomics (BNO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Bionomics Stock (ASX:BNO) 30 days 90 days 365 days Advanced Chart Get Bionomics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume386,458 shsAverage VolumeN/AMarket CapitalizationA$13.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. Read More Receive BNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter. Email Address BNO Stock News HeadlinesBionomics Stock Price HistoryMay 27, 2025 | investing.comBNO Makes Bullish Cross Above Critical Moving AverageOctober 5, 2024 | nasdaq.comMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Bionomics Ltd: Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress DisorderAugust 2, 2024 | finanznachrichten.deBionomics ADR (BNOX) Earnings Dates & ReportsDecember 18, 2023 | investing.comBionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic GrowthJuly 3, 2023 | finance.yahoo.comBionomics Ltd: Bionomics Reports Promising Full Results Analysis from PREVAIL Phase 2 Study of BNC210 Social Anxiety Disorder (SAD)March 9, 2023 | finanznachrichten.deBionomics First Half 2023 Earnings: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)February 24, 2023 | finance.yahoo.comSee More Headlines BNO Stock Analysis - Frequently Asked Questions How were Bionomics' earnings last quarter? Bionomics Limited (ASX:BNO) issued its earnings results on Friday, February, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter. Bionomics had a negative trailing twelve-month return on equity of 116.12% and a negative net margin of 14,558.34%. What other stocks do shareholders of Bionomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include McDermott International (MDR), Pacific Drilling (PACDQ), OreCorp (ORR), ORBCOMM (ORBC), Lithium Power International (LPI), Lithium Australia (LIT) and CocaCola (KO). Company Calendar Last Earnings2/15/2019Today7/18/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:BNO CIKN/A Webwww.bionomics.com.au Phone+61-8-83546100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$24.91 million Net Margins-14,558.34% Pretax MarginN/A Return on Equity-116.12% Return on Assets-20.98% Debt Debt-to-Equity Ratio0.20 Current Ratio3.30 Quick Ratio12.02 Sales & Book Value Annual SalesA$6.02 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.69 Book ValueA$1.09 per share Price / BookN/AMiscellaneous Outstanding Shares1,470,000,000Free FloatN/AMarket CapA$13.22 million OptionableNot Optionable Beta2.13 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (ASX:BNO) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTurn $1K into $50K with This DeFi GemTHREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored“All the land that you see I will give to you and your offspring forever…”“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bionomics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bionomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.